BEONTAG
17.1.2023 12:01:56 CET | Business Wire | Press release
Today, Beontag – one of the world’s largest manufacturers of self-adhesives and smart tags (such as digital labels, and labeling technology solutions like RFID and NFC) – announced that Tags Lux Sarl., a wholly owned subsidiary of the Company, has secured and closed a binding agreement for a syndicated loan of €120 million with global banks and Deutsche Bank as sole lead arranger.
Beontag, the second largest provider of digital RFID and NFC solutions for some of the world’s biggest fashion and consumer brands, is expected to achieve €550 Million in revenue for 2022, with international and national acquisitions, integrations and expansion contributing to significant top-line growth from pro forma actualized revenues of more than €400 Million in 2021. This is the first significant, international capital raise by the Brazilian-founded company – with operations now spanning more than 15 international facilities and a presence in over 40 countries.
Terms of Syndicated Facility
- The syndicated loan shall mature within 60 months from closing date with 18 months grace period, including a possibility of prepayment from the 18th month.
- Beontag intends to use the net proceeds from the issuance to primarily refinance its existing debt throughout the group. Any excess proceeds will be used to support organic strategic initiatives across multiple geographies and enhance liquidity.
- The transaction is expected to be leverage-neutral after closing.
- The loan shall carry an interest rate of EURIBOR plus 4.5% per annum and contains incentivised terms that are linked to Beontag 2030 ESG strategy, which is aligned to the United Nations Sustainable Development Goals (SDGs). Every year, Beontag will seek third-party verification to certify and report upon progress against the ESG-related terms agreed.
Global Expansion, Borderless Solutions
Beontag’s Chief Financial Officer, Pedro Christ, commented: “Investment is a key aspect of our journey to become a truly borderless, end-to-end solutions provider of self-adhesive label stock and IoT solutions. And we believe this syndicated capital raise is a good example of the confidence of international investors in Beontag’s global strategy, as well as our current operational fundamentals.
For 2023, and beyond, we are excited to continue to innovate and expand our solutions to meet our clients’ demands for future-focused support, all while taking care to improve our ESG credentials and reduce the impact of our sector on the planet.”
The Managing Director of Global Emerging Markets from Deutsche Bank, Ricardo Cunha, added: “We are delighted to partner with Beontag for this transaction. This commitment, with and added ESG incentive, reflects our confidence in both the strength and sustainable intention of their innovative plans for the sector.
We look forward to keep supporting Beontag as the company expands into different markets and geographies.”
ENDS
ABOUT BEONTAG
For more than 40 years, Beontag has been dedicated to developing the future of pressure sensitive label stock and RFID technology, being world leaders in both segments. Today the company’s dedicated team, leading technology, global reach, and capabilities help the world work more efficiently, reliably, and safely. Beontag´s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill Beontag´s mission to be a digital enabler.
With modern manufacturing facilities, permanent investment and a highly qualified team, the company has been expanding its business globally and is one of the largest and most respected self-adhesive companies in Latin America. It also operates in the technology sector and has a wide portfolio of Internet of Things (IoT) solutions, focused on the manufacture of radiofrequency smart labels, as well as on the development of software for the integration of the logistics chain, traceability, and product authentication.
To learn more, visit: https://beontag.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom